CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
MicroSert has developed BlueDot, a long-acting ocular implant designed for the sustained delivery of treatments for retinal diseases. This innovative device is implanted in the tear duct and provides a refillable solution that lasts up to two years, significantly improving patient comfort and treatment adherence.
Seventy-six million people will suffer from blindness by 2020.
Age-related retinal disorders - macular degeneration (AMD) and diabetic macular edema (DME) are two of the leading causes of blindness in the world.
About 200,000 new cases of advanced, age-related AMD identified each year in the United States and between 14.9 and 21.5 million cases of early AMD, and between 3.9 and 4.8 million cases of late AMD is expected in Europe by 2040.
The complexity of eye anatomy presents challenges for trea…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
